bimekizumab

Details

Files
Generic Name:
bimekizumab
Project Status:
Complete
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
UCB Canada Inc.
Brand Name:
Bimzelx
Project Line:
Reimbursement Review
Project Number:
SR0698-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​For the treatment of moderate to severe plaque psoriasis (PsO) in adult patients who are candidates for systemic therapy or phototherapy
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open19-Jul-21
Call for patient/clinician input closed13-Sep-21
Clarification:

- Patient input submission received from the Canadian Psoriasis Network (CPN) and Canadian Association of Psoriasis Patients (CAPP)

Submission received17-Aug-21
Submission accepted31-Aug-21
Review initiated01-Sep-21
Draft CADTH review report(s) provided to sponsor for comment18-Nov-21
Deadline for sponsors comments29-Nov-21
CADTH review report(s) and responses to comments provided to sponsor14-Jan-22
Expert committee meeting (initial)26-Jan-22
Draft recommendation issued to sponsor18-Feb-22
Draft recommendation posted for stakeholder feedback03-Mar-22
End of feedback period17-Mar-22
Final recommendation issued to sponsor and drug plans30-Mar-22
Final recommendation posted18-Apr-22
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)13-Apr-22
CADTH review report(s) posted31-May-22